200
Participants
Start Date
February 26, 2020
Primary Completion Date
December 31, 2027
Study Completion Date
December 31, 2028
ABSK-011
"During the escalation part, the administration of oral ABSK-011 will be guided by 3+3design based on safety data collected until a maximum tolerated dose (MTD) has been identified. The first dose level will be administered as QD, and different dosing frequencies (e.g., BID) may be explored in subsequent doses depending on emerging safety and pharmacokinetic data. A separate food effect cohort may be conducted. In expansion part, patients will be treated at the selected RDE dose level."
NOT_YET_RECRUITING
Icahn School of Medicine at Mount Sinai, New York
NOT_YET_RECRUITING
Mayo Clinic, Jacksonville
RECRUITING
Moffitt Cancer Center, Tampa
NOT_YET_RECRUITING
Mayo Clinic, Rochester
RECRUITING
MD Anderson Cancer Center, Houston
NOT_YET_RECRUITING
Mayo Clinic, Phoenix
COMPLETED
The First Affiliated Hospital of Bengbu Medical College, Bengbu
RECRUITING
Beijing Tsinghua Changgung Hospital, Beijing
WITHDRAWN
The Fifth Medical Center of the General Hospital of the Chinese People's Liberation Army, Beijing
RECRUITING
Chongqing Cancer Hospital, Chongqing
COMPLETED
Fujian Provincial Cancer Hospital, Fuzhou
COMPLETED
Sun Yat Sen Memorial Hospital, Guangzhou
COMPLETED
Guangxi Zhuang Autonomous Region People's Hospital, Nanning
COMPLETED
Weifang People's Hospital, Weifang
RECRUITING
Harbin Medical University Cancer Hospital, Haerbin
COMPLETED
First Affiliated Hospital of Henan University of Science and Technology, Luoyang
COMPLETED
Henan Cancer Hospital, Zhengzhou
COMPLETED
Hubei Cancer Hospital, Wuhan
RECRUITING
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology, Wuhan
COMPLETED
Hunan Cancer Hospital, Changsha
WITHDRAWN
Hunan Provincial People's Hospital, Changsha
COMPLETED
Suzhou University Affiliated Second Hospital, Suzhou
COMPLETED
Tonghua Central Hospital, Tonghua
COMPLETED
Shengjing Hospital of China medical university, Shenyang
COMPLETED
General Hospital of Ningxia Medical University, Yinchuan
COMPLETED
Jinan Central Hospital, Jinan
COMPLETED
Linyi Cancer Hospital, Linyi
WITHDRAWN
The First Affiliated Hospital of Xi'an Jiaotong University, Xian
RECRUITING
Mianyang Central Hospital, Mianyang
WITHDRAWN
Ningbo Huamei Hospital, University of Chinese Academy of Sciences, Ningbo
COMPLETED
National Cheng Kung University Hospitals, Tainan City
COMPLETED
Nation Taiwan University Hospital, Taipei
Lead Sponsor
Abbisko Therapeutics Co, Ltd
INDUSTRY